Serum level of soluble tumour necrosis factor receptor II (75 kDa) indicates inflammatory activity of sarcoidosis

Ziegenhagen, Manfred W.; Fitschen, J.; Martinet, Nadine; Schlaak, M; Müller–Quernheim, Joachim

doi:10.1046/j.1365-2796.2000.00685.x

Cited by 22 publications

(17 citation statements)

References 30 publications

(34 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[11] Several factors, including skeletal muscle weakness, oral corticosteroid treatment, myositis, pulmonary hypertension, respiratory status, depression, fatigue, and high circulating levels of tumor necrosis factor-α (TNF-α) significantly reduce the 6MWD in sarcoidosis. [11131–37] In the current investigation, 6MWD was significantly affected by gender, pulmonary function, dyspnea, CRP score, and SpO 2 at the completion of the 6MWT. The total distance achieved by the entire cohort was markedly reduced.…”

Section: Discussionmentioning

confidence: 59%

The six-minute walk test in patients with pulmonary sarcoidosis

Alhamad¹

2009

Ann Thorac Med

View full text Add to dashboard Cite

BACKGROUND:The 6-min walk test (6MWT) is a useful tool to assess prognosis and functional impairment in various pulmonary diseases.AIMS:To evaluate functional capacity during various stages of pulmonary sarcoidosis and develop a scoring system clinical radiological physiological score (CRP) that can potentially be used to assess the functional status among patients with sarcoidosis.MATERIALS AND METHODS:We performed a retrospective study on 26 patients diagnosed with pulmonary sarcoidosis from 2001 to 2007. All patients completed the 6MWT. The parameters assessed during the test included spirometry, arterial blood gas, 6-min walk distance (6MWD), Borg dyspnea score, and initial and end oxygen saturation.RESULTS:Females covered a significantly shorter distance than males (343 m (223–389) vs. 416.5 m (352–500); P < 0.0001). In addition, females had a significantly lower SpO2 at the end of the 6MWT than males (90.5 (61–99) vs. 96 (75–98); P < 0.03). The 6MWD was inversely correlated with the final Borg score (ρ = −0.603, P = 0.004) and the CRP score (ρ = −0.364, P = 0.047) and positively correlated with forced expiratory volume in 1 s (FEV1) % (ρ = 0.524, P = 0.006) and forced vital capacity (FVC) % (ρ = 0.407, P = 0.039).CONCLUSIONS:Female gender, FEV1%, final Borg score, FVC%, CRP score, and SpO2 at the end of the 6MWT are associated with reduced 6MWD. It appears that Saudi patients diagnosed with sarcoidosis have a markedly reduced walking distance compared with other races. The effect of race and ethnicity and the utility of the CRP score as a potential marker to assess functional status require further exploration.

show abstract

Section: Discussionmentioning

confidence: 59%

The six-minute walk test in patients with pulmonary sarcoidosis

Alhamad¹

2009

Ann Thorac Med

View full text Add to dashboard Cite

show abstract

“…Analysis of median levels of individual cytokines confirmed previously published studies showing upregulation of IL-1b, IL-6, IL-8, IL-10, IL-12p40, IL-15, IL-17, TNF-RI, TNF-RII, MIP1a, MIP-1b, MCP-1, HGF and IP-10 in SSc patients [13][14][15][16][17][18][19][20][21][22][23] and upregulation of IL-8, TNF-RI, TNF-RII, IL-12p40, MIP-1a, MIP1b, MIG and IP-10 in sarcoidosis [24][25][26][27]. Novel findings, as far as we are aware, for other individual biomarkers included increased serum IFN-a, MIG, IP-10, DR5 and eotaxin levels in SSc patients and elevated serum levels of RANTES, DR5, EGF and HGF in sarcoidosis compared with healthy controls.…”

Section: Discussionmentioning

confidence: 99%

Multiplex immune serum biomarker profiling in sarcoidosis and systemic sclerosis

Beirne¹,

Pantelidis²,

Charles³

et al. 2009

European Respiratory Journal

View full text Add to dashboard Cite

Multiplex protein technology has the potential to identify biomarkers for the differentiation, classification and improved understanding of the pathogenesis of interstitial lung disease. The aim of this study was to determine whether a 30-inflammatory biomarker panel could discriminate between healthy controls, sarcoidosis and systemic sclerosis (SSc) patients independently of other clinical indicators. We also evaluated whether a panel of biomarkers could differentiate between the presence or absence of lung fibrosis in SSc patients.We measured 30 circulating biomarkers in 20 SSc patients, 21 sarcoidosis patients and 20 healthy controls using Luminex bead technology and used Fisher's discriminant function analysis to establish the groups of classification mediators.There were significant differences in median concentration measurements between study groups for 20 of the mediators but with considerable range overlap between the groups, limiting group differentiation by single analyte measurements. However, a 17-analyte biomarker model correctly classified 90% of study individuals to their respective group and another 14-biomarker panel correctly identified the presence of lung fibrosis in SSc patients.These findings, if they are corroborated by independent studies in other centres, have potential for clinical application and may generate novel insights into the modulation of immune profiles during disease evolution.

show abstract

“…These molecules are released by alveolar cells [220,222] and elevated serum levels related to the clinical course are observed in active sarcoidosis and other chronic inflammatory disorders [221,[223][224][225][226]. BAL cell release and BAL fluid content of these cytokines do not correlate with their respective serum levels [221,224,227], which might be explained by the absence of a basal membrane leakage or only a limited defect of the basal membrane in sarcoidosis [228,229] and a release of these molecules in other compartments of the body with easier access to serum [221,224,230].…”

Section: Cytokine Networkmentioning

confidence: 99%

Sarcoidosis: immunopathogenetic concepts and their clinical application

1998

View full text Add to dashboard Cite

Our understanding of the immunopathogenesis of sarcoidosis has been advanced by studies of bronchoalveolar lavage cells. Activated macrophages and T-cells have been identified in different compartments of the sarcoid lung and the characteristics of the activation suggest that the cells become activated in the course of a normal immune response. The immune cells communicate via a cytokine network and the measuring of cytokine levels yields subgroups of sarcoidosis patients with different courses of the disease indicating different states of activation of the disease-mediating immune cells. The causative agent of sarcoidosis has not yet been identified; however, some of the described mechanisms can be clinically applied either to detect patients at risk of deterioration or to develop new therapeutic strategies. Using these approaches methotrexate, pentoxifylline and thalidomide have been identified as drugs which effectively suppress sarcoid inflammation and the serum level of soluble interleukin-2 receptors has been delineated to be a serum marker of sarcoid inflammation. Furthermore, analysing the pulmonary cytokine network in sarcoidosis will yield new staging parameters possibly supplying prognostic information and guiding therapeutic intervention.

show abstract

Serum level of soluble tumour necrosis factor receptor II (75 kDa) indicates inflammatory activity of sarcoidosis

Cited by 22 publications

References 30 publications

The six-minute walk test in patients with pulmonary sarcoidosis

The six-minute walk test in patients with pulmonary sarcoidosis

Multiplex immune serum biomarker profiling in sarcoidosis and systemic sclerosis

Sarcoidosis: immunopathogenetic concepts and their clinical application

Contact Info

Product

Resources

About